World No. 1 Aryna Sabalenka recently addressed the Women’s Tennis Association's new mandate for genetic testing. The policy requires all players to undergo screening for the SRY gene, which is a marker typically found on the Y chromosome. The tour implementation marks a new step in how professional leagues handle eligibility standards for biological sex in competition.
During a press conference held at the National Bank Open in Toronto, Sabalenka expressed support for the measure. She stated that the focus remains on maintaining fairness within the sport. The player noted that biological differences are a factor in performance, adding that she is willing to participate in the testing as required.
The WTA policy clarifies that the testing process distinguishes between biological sex and gender identity for the purpose of maintaining competitive equity. The rules define the categories based on the presence or absence of the SRY gene rather than legal status or personal identity. This approach is intended to provide clear guidelines for athletes competing on the professional tour.
This move by the WTA aligns with broader discussions regarding participation requirements across international sports. The one-time mandatory screening is also a requirement for athletes aiming to compete at the 2028 Los Angeles Olympics. As these protocols take effect, players are adjusting to the new administrative standards while preparing for their upcoming matches on the circuit.